Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06578299
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-27
Brief Title:
Inetetamab Combined With Paclitaxel WithWithout Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Real World Study of First Line Treatment of HER2 Positive RecurrentMetastatic Breast Cancer With Inetetamab Combined With Paclitaxel WithWithout PertuzumabINTPOWER
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to comprehensively evaluate the HER2 positive recurrentmetastatic breast cancer patients in the real world who receive the combination of Inetetamab and Paclitaxel Pertuzumab including basic characteristics efficacy and safety The results of this study are helpful to further understand the efficacy and safety of HER2 positive patients with recurrentmetastatic breast cancer who receive the combination of Inetetamab and Paclitaxel Pertuzumab in the first line and help clinical decision-making
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None